OMS906
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1Active
Key Facts
Indication
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase
Phase 1
Status
Active
Company
About Omeros Corporation
Omeros Corporation is a publicly traded biopharmaceutical company that leverages its expertise in immunology and inflammation to develop novel therapeutics. The company has built a portfolio around its commercial ophthalmology product, OMIDRIA, and is advancing multiple clinical-stage candidates, most notably its MASP-2 inhibitor narsoplimab for hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). Omeros's strategy involves targeting both niche, high-need orphan diseases and larger commercial markets through its proprietary research platforms.
View full company profileTherapeutic Areas
Other Paroxysmal Nocturnal Hemoglobinuria (PNH) Drugs
| Drug | Company | Phase |
|---|---|---|
| EMPAVELI/Aspaveli (pegcetacoplan) | Apellis Pharmaceuticals | Approved |
| Empaveli (pegcetacoplan) | bioRASI | Approved |